community download

Presentation: Bridging the gap between prophylactic and therapeutic vaccines

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

How do you bridge the gap between prophylactic and therapeutic vaccines?

“A vaccine that ‘treats’ a disease before it causes morbidity would bridge the gap between prophylactics and therapeutics.”

But how?

Download this presentation to discover more about bridging the gap between prophylactic and therapeutic vaccines including:
• The next-best thing to prophylaxis
• Therapy of still-healthy patients requires validated biomarkers and a diagnostic-compliant target population
• Avoiding adjuvant IN vaccine formulations reduces adjuvant-specific regulatory risks
• ProCervix, first clinical-stage therapeutic vaccine to prevent disease progression in healthy HR-HPV-infected patients
Dr Benedikt Timmerman, Chief Executive Officer, Genticel